Compare KN & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KN | ARQT |
|---|---|---|
| Founded | 1946 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.9B |
| IPO Year | 2013 | 2020 |
| Metric | KN | ARQT |
|---|---|---|
| Price | $39.82 | $24.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $28.00 | ★ $34.00 |
| AVG Volume (30 Days) | 906.7K | ★ 1.6M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.94 | 88.79 |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $593,200,000.00 | $376,072,000.00 |
| Revenue This Year | $9.40 | $34.85 |
| Revenue Next Year | $6.98 | $29.39 |
| P/E Ratio | $365.82 | ★ N/A |
| Revenue Growth | 7.17 | ★ 91.34 |
| 52 Week Low | $16.78 | $13.06 |
| 52 Week High | $40.24 | $31.77 |
| Indicator | KN | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 63.67 | 66.61 |
| Support Level | $23.97 | $22.41 |
| Resistance Level | $39.92 | $25.25 |
| Average True Range (ATR) | 1.69 | 0.94 |
| MACD | -0.07 | 0.48 |
| Stochastic Oscillator | 88.13 | 85.49 |
Knowles Corp is engaged in the manufacturing of micro-acoustic microphones and balanced armature speakers, audio solutions, high-performance capacitors, and radio frequency filtering products. It operates in two segments; the Precision Devices segment specializes in the design and delivery of high-performance capacitor products and RF solutions; and Medtech & Specialty Audio segment designs and manufactures microphones and balanced armature speakers used in applications. The majority of its revenue comes from the Precision Devices. Geographically, it operates in United States, Asia, Other Americas, Europe and Others, out of which United States generates maximum revenue.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.